Healthcare
Live Price
Offline$10.10
+0.00% today
1Y Change
+201.53%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Trulieve Cannabis Corp. (TCNNF) is a Healthcare stock with a market cap of $1.63B and listed on OTC. The stock last traded around $10.10 and up 201.5% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +1.3%, EPS growth of +24.4%, a dividend yield of 0.0%. What stands out right now is revenue +1.3%, EPS +24.4%, free cash flow +55.1% with operating margin 12.6% and ROIC -7.2%. Valuation is more restrained than many high-expectation growth names at price/sales 1.4. Stock Foundry combines TCNNF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TCNNF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TCNNF Max Drawdown
-54.42%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TCNNF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$938.4M
-24.3% YoY
FY Net Income
$18.0M
+108.8% YoY
Free Cash Flow
-$293.2M
-81.6% YoY
Revenue Growth
+1.3%
EPS Growth
+24.4%
Gross Margin
57.7%
Net Margin
-9.9%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.2B | 1.2B | 1.1B | 1.2B | 938M |
| Gross Profit | 604M | 716M | 589M | 682M | 566M |
| Operating Income | 162M | 98M | -222M | 109M | 197M |
| EBITDA | 334M | 259M | -33M | 240M | 284M |
| Net Income | -118M | -155M | -527M | -205M | 18M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 255M | 239M | 201M | 212M | 231M |
| Total Assets | 2.7B | 2.9B | 2.7B | 3.4B | 3.4B |
| Total Liabilities | 1.6B | 1.6B | 1.3B | 1.5B | 1.3B |
| Shareholder Equity | 1.2B | 1.3B | 1.4B | 1.9B | 2.1B |
| Total Debt | 670M | 824M | 793M | 1.0B | 859M |
| Net Debt | 415M | 586M | 591M | 817M | 628M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
13M
-44.2% YoY
Capital Expenditures
306M
-65.8% YoY
Free Cash Flow
293M
-81.6% YoY
Key ratios
Gross Margin
57.7%
Operating Margin
12.6%
Net Margin
-9.9%
ROE
-9.7%
Debt / Equity
0.58x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.